Ask about this productRelated genes to: UGT1A9 antibody
- Gene:
- UGT1A9 NIH gene
- Name:
- UDP glucuronosyltransferase family 1 member A9
- Previous symbol:
- -
- Synonyms:
- HLUGP4, LUGP4, UGT1AI
- Chromosome:
- 2q37.1
- Locus Type:
- complex locus constituent
- Date approved:
- 2000-06-22
- Date modifiied:
- 2016-10-05
Related products to: UGT1A9 antibody
Related articles to: UGT1A9 antibody
- Irinotecan (CPT-11) is a prodrug that is bioactivated to SN-38, which is primarily cleared via UGT1A1-mediated glucuronidation. Its complex metabolism, which also involves CYP3A-mediated oxidation, makes irinotecan highly susceptible to enzyme-mediated drug-drug interactions (DDIs). This study aimed to develop and qualify an adult whole-body physiologically based pharmacokinetic (PBPK) model of irinotecan and its metabolites (SN-38, SN-38G, and APC) to predict systemic pharmacokinetics and UGT1A1/CYP3A-mediated DDIs. - Source: PubMed
Publication date: 2026/05/26
Chen BowenLi LongjieXu WenhangXu HaipingZhu XinyanHe QingfengZhu XiaoChi-Lui Ho PaulXiang XiaoqiangJi Peiying - Kidney transplant recipients are at risk for Pneumocystis jirovecii pneumonia (PJP), particularly under profound immunosuppression. Mycophenolic acid (MPA) is widely used after transplantation and is associated with interindividual variability in exposure and hematologic toxicity. Genetic variation affecting MPA metabolism and pharmacodynamics may contribute to lymphopenia and PJP. - Source: PubMed
Publication date: 2026/06/03
Henskens NathalieLagrou Katriende Loor HenrietteCuypers LizeKuypers Dirk - 5-Fluorouracil (5-FU) is a widely utilized antimetabolite in colorectal cancer chemotherapy, primarily exerting its cytotoxic effects by irreversibly inhibiting thymidylate synthase (TS). This inhibition leads to a reduction in deoxythymidine monophosphate (dTMP), which disrupts DNA synthesis and repair. A major challenge in 5-FU treatment is the dose-limiting toxicity of chemotherapeutic-induced intestinal mucositis. Da-Bu-Pi Decoction (DBPD), a well-established formula in traditional Chinese medicine for treating spleen-stomach deficiency, is often used to enhance spleen qi and balance the middle jiao. While growing clinical evidence points to the therapeutic benefits of DBPD in alleviating 5-FU-induced mucositis, the underlying molecular mechanisms remain largely undefined. - Source: PubMed
Publication date: 2026/04/30
Wang ShunZhiLi YalingMa JingLi JunJieHuang DanWa XiaoXiaZhou YuCenLiu YongQi - Vonifimod is a novel sphingosine-1-phosphate receptor (S1PR) modulator with selectivity for S1PR1 and S1PR4 that is under development for the treatment of autoimmune disease. No reports on vonifimod metabolism exist except for the formation of active vonifimod-phosphate in rats. The in vitro metabolic pathways and drug interaction potentials of vonifimod were characterized by identifying the metabolites of vonifimod in human hepatocytes via liquid chromatography-high-resolution mass spectrometry and determining the inhibitory effects of vonifimod on major cytochrome P450 (CYP) and UDPGA-glucuronosyltransferase (UGT) enzyme activities in human liver microsomes. The incubation of vonifimod with human hepatocytes resulted in the formation of nine metabolites, including hydroxy-vonifimod (M1 and M2), inactive carboxylic acids (M3 - M6), active vonifimod-phosphate (M7), and M3 glucuronides (M3-G1 and M3-G2). ω-Hydroxylation of vonifimod to M2 at the methyl terminus of the decyl chain was catalyzed mainly by CYP4F2 enzymes, which were further oxidized to four carboxylic acid metabolites (M3 - M6). UGT1A7, UGT1A8, UGT1A9, and UGT1A10 catalyzed the formation of M3-G2 from M3. Vonifimod revealed the negligible and weak inhibition of major CYP and UGT enzyme activities at 50 µM in human liver microsomes, suggesting that vonifimod has low potential for drug-drug interactions. These findings suggest hepatic metabolism to be the primary elimination pathway for vonifimod. - Source: PubMed
Publication date: 2025/12/04
Kim Eun JeongLee Min SeoPark Yang HaeLee BongyongLee Hye Suk - Procyanidins are abundant dietary flavonoids with diverse pharmacological activities; however, their Absorption, Distribution, Metabolism, and Excretion (ADME) remain incompletely characterized. MT-8, a procyanidin B3 derivative with an ethyl group at the C8 position of the A-ring, is a promising preclinical candidate for cerebral ischemia treatment and is currently in the Investigational New Drug (IND) application stage. This study aimed to systematically characterize the ADME profile of MT-8 in male Sprague-Dawley (SD) rats following intravenous administration to provide a reference for ADME studies of procyanidin-related compounds. - Source: PubMed
Publication date: 2026/04/14
Xu HaiboLi ZhiqiangWang LinweiZhang HeyanhaoChen ShuoyueChen LijuanGao YangZhao YuqingBao YuanwuDiao XingxingChang JunTang Chongzhuang